A flurry of recent randomized, placebo-controlled trials assessing dissimilar pharmacotherapeutic treatment options for fibromyalgia (FM) have been presented in the past few years.
This review evaluates these trials in light of recent pathophysiological concepts germane to FM, including:
• Mood disorders,
• Autonomic dysregulation,
• Altered sleep stage architecture,
• And the diagnostic tender point controversy.
Studies with gabapentin, pregabalin, duloxetine, milnacipran, sodium oxybate, and pramipexole for treatment of FM are discussed.
Source: Current Pain and Headache Reports, Dec 2008;12(6):393-398. PMID: PMID: 18973730, by Holman AJ. Pacific Rheumatology Research, Renton Washington, USA. [E-mail: AJHSeattle@aol.com]